| 生物活性 |
TBE 31 is an orally active Keap1/Nrf2 pathway activator and NQO1 inducer with a Dm value of 1.1 nM for NQO1; it binds to Keap1 cysteine residues to inhibit Nrf2 ubiquitination and degradation, thereby activating ARE-dependent gene expression, and it induces cytoprotective enzymes including NQO1 and GST isoforms, promotes Nrf2 accumulation, and upregulates Nrf2-regulated antioxidant and lipid metabolism-related genes, while also inhibiting pro-inflammatory responses, AFB1-DNA adduct formation, endoplasmic reticulum stress, apoptosis, liver fibrosis, oxidative stress, and ChREBP expression, reducing tumor number in a UV-induced skin carcinogenesis mouse model, enhancing nerve growth factor-induced neurite outgrowth, and attenuating LPS-induced serum TNF-α levels and immobility time in mice, and it can therefore be used in research related to liver cancer, skin cancer, inflammation-related depression, and non-alcoholic steatohepatitis. |
体内研究 (In Vivo) |
TBE-31 (0.03-0.3 μM;局部给药;每 24 小时 1 次;共给药 3 次) 可在健康 SKH-1 无毛小鼠中剂量依赖性地诱导皮肤 NQO1 活性升高至 4.9 倍,GST 活性升高至 1.5 倍。 TBE-31 (按每 3 g 饲料添加 0.1-0.3 μM;口服;每日一次;持续 11 天) 可剂量依赖性地诱导健康 SKH-1 无毛小鼠的肝脏、皮肤和胃 (而非大脑皮层) 中细胞保护酶的活性和蛋白水平升高至最高 5.0 倍,且无毒性。 TBE-31 (10 μM/kg;口服;单次给药) 可使雌性 C57BL/6 小鼠肝脏 NQO1 活性升高 2.4 倍,心脏 NQO1 活性升高 1.5 倍。 TBE-31 (每只动物 40 nM;局部给药;每周 2 次;约 30 周) 可显著降低同时接受 Azathioprine (MS-M69029) 免疫抑制的紫外线诱导皮肤癌变小鼠模型的肿瘤数量与负荷。 TBE-31 (1-10 mg/kg;口服;单次给药) 可对 LPS (MS-X54539) 诱导的 TNF-α 升高发挥剂量依赖性抗炎作用,且在 10 mg/kg 剂量下可显著改善 LPS 处理小鼠的抑郁样行为。 TBE-31 (5 nM/g;口服;每周 3 次;持续 6 周) 处理可逆转饮食诱导的已发病 Nrf2+/+ 小鼠的胰岛素抵抗,减轻肝脏脂肪变性,并改善非酒精性脂肪性肝炎 (NASH) 和肝纤维化;NAS 降低 40.8%,同时糖稳态、氧化应激及炎症标志物均得到改善。 TBE-31 (5 nM/g;口服;每周 3 次;持续 6 周) 需要功能性 Nrf2 才能改善已建立饮食诱导疾病小鼠的胰岛素敏感性、减轻肝脂肪变性并缓解 NASH,因为在 Nrf2-/- 小鼠中这些有益作用完全消失,而 Nrf2+/+ 小鼠的 NAS 降低了 52.9%。
| Animal Model: |
SKH-1 hairless (female, 10-12 weeks old) |
| Dosage: |
0.03 μM; 0.1 μM; 0.3 μM |
| Administration: |
topical; every 24 h; 3 doses |
| Result: |
Elevated NQO1 specific activity 3.5-fold (0.03 μmol dose), 4.2-fold (0.1 μM dose), and 4.9-fold (0.3 μM dose) compared to control. Elevated GST specific activity 1.3-fold (0.03 μmol dose), 1.5-fold (0.1 μM dose), and 1.5-fold (0.3 μM dose) compared to control. Induced statistically significant enzyme activity increases. |
| Animal Model: |
SKH-1 hairless (10-12 weeks old) |
| Dosage: |
0.1 μM/3 g diet; 0.3 μM/3 g diet |
| Administration: |
oral; daily; 11 days |
| Result: |
Increased liver NQO1 activity 2.4-fold (0.1 μM dose) and 3.5-fold (0.3 μM dose); increased liver GST activity 2.4-fold (0.1 μM dose) and 3.7-fold (0.3 μM dose); increased liver GSTA1 protein levels 1.4-fold (0.1 μM dose) and 1.7-fold (0.3 μM dose); increased liver GSTM1 protein levels 1.6-fold (0.1 μM dose) and 1.9-fold (0.3 μM dose); increased liver GSTP1 protein levels 2.2-fold (0.1 μM dose) and 3.6-fold (0.3 μM dose). Increased skin NQO1 activity 2.2-fold (0.1 μM dose) and 3.5-fold (0.3 μM dose); increased skin GST activity 1.3-fold (0.1 μM dose) and 2.0-fold (0.3 μM dose). Increased stomach NQO1 activity 3.8-fold (0.1 μM dose) and 4.5-fold (0.3 μM dose); increased stomach GST activity 3.5-fold (0.1 μM dose) and 5.0-fold (0.3 μM dose); increased stomach GSTA1 protein levels 2.2-fold (0.1 μM dose) and 2.4-fold (0.3 μM dose); increased stomach GSTM1 protein levels 2.4-fold (0.1 μM dose) and 3.3-fold (0.3 μM dose); increased stomach GSTP1 protein levels 2.3-fold (0.1 μM dose) and 3.0-fold (0.3 μM dose). Induced statistically significant enzyme activity and protein level increases. Caused no observed toxicity. Showed no changes in cerebral cortex cytoprotective enzyme activities or protein levels.
|
| Animal Model: |
C57BL/6 (female, 6-12 weeks of age) |
| Dosage: |
10 μM/kg |
| Administration: |
p.o.; single dose |
| Result: |
Increased hepatic NAD(P)H:quinone oxidoreductase 1 (NQO1) specific enzyme activity 2.4-fold compared to vehicle-treated controls. Increased cardiac NQO1 specific enzyme activity 1.5-fold compared to vehicle-treated controls. |
| Animal Model: |
SKH-1 hairless |
| Dosage: |
40 nM per animal |
| Administration: |
topical; twice weekly; ~30 weeks |
| Result: |
Dramatically reduced tumor multiplicity and burden compared to controls. |
| Animal Model: |
C57BL/6N (adult male, 20-26 g, LPS-induced inflammation-associated depression-like behavior) |
| Dosage: |
1 mg/kg; 3 mg/kg; 10 mg/kg |
| Administration: |
p.o.; single dose |
| Result: |
Attenuated LPS-induced increases in serum TNF-α levels in a dose-dependent manner, with the 10 mg/kg dose reaching statistical significance. Did not alter spontaneous locomotion in LPS-treated mice at 10 mg/kg. Significantly reduced LPS-induced increases in immobility time in the TST and FST at 10 mg/kg compared to LPS-only treated mice. Did not affect immobility time in control mice when administered alone. |
| Animal Model: |
C57BL/6 wild-type (Nrf2+/+) (male, 8-10 weeks of age, fed sequential high-fat plus 55% fructose (HF55Fr) diet for 15 weeks followed by high-fat plus 30% fructose (HF30Fr) diet for 9 weeks to induce NASH and insulin resistance) |
| Dosage: |
5 nM/g body weight |
| Administration: |
p.o.; 3 times weekly; 6 weeks |
| Result: |
Enhanced glucose clearance during ITT and GTT, and reduced hepatic gluconeogenesis during PTT compared to vehicle controls. Decreased post-intervention weight gain, fasted plasma insulin, plasma cholesterol, and plasma alanine aminotransferase activity relative to vehicle-treated HF-fed mice. Decreased liver triglyceride and cholesterol levels, reduced mRNA expression of Adrp, increased hepatic mRNA for lipid catabolism genes (Acox2, Ces1g, Acot7, Ppara, Cpt1a, Scad), decreased expression of lipogenic transcription factors (Srebf1, Mlxipl, Lxra, Xbp1s) and their target lipid synthesis enzymes (Acaca, Acly, Fasn, Scd1, Dgat2, Lipin1, Mgpat), and increased mRNA for lipid export genes (Mttp, ApoB). Reduced hepatic protein levels of Bip, phospho-Ire1α, Xbp1s, phospho-eIf2α, and Atf4, and decreased mRNA for Atf4 and Chop relative to vehicle controls. Attenuated nuclear accumulation of NF-κB p65, p52, p50; increased IκBα protein; decreased phospho-IKKα/β and phospho-JNK; and reduced mRNA for proinflammatory genes (Cox2, Nos2, Il1β, Ifng, Tnfa, Mcp1, Elastase, Mpo) relative to vehicle controls. Reduced cleavage of Parp, caspase-9, and caspase-3; increased Bcl-2 mRNA; and decreased mRNA for Tgfβ, Col1a1, and α-Sma relative to vehicle controls. Decreased hepatic malondialdehyde and protein carbonyl levels, increased GSH/GSSG ratio, and induced mRNA for antioxidant Nrf2-target genes (Gclc, Gclm, Gpx2, Nqo1, Gstm1, Hmox1, Txn1, Txnrd1, Slc7a11, Cat, Prdx6) relative to vehicle controls. Reduced NAFLD Activity Score (NAS) from 4.9 to 2.9, with significant decreases in hepatocyte ballooning and fibrosis relative to vehicle controls. |
| Animal Model: |
C57BL/6 wild-type (Nrf2+/+) and Nrf2-knockout (Nrf2-/-) (male, 8-10 weeks of age, fed high-fat plus 30% fructose (HF30Fr) diet for 10 weeks to induce NASH and insulin resistance) |
| Dosage: |
5 nM/g body weight |
| Administration: |
p.o.; 3 times weekly; 6 weeks |
| Result: |
Enhanced insulin sensitivity during ITT and reduced hepatic gluconeogenesis during PTT compared to vehicle controls in Nrf2+/+ mice. Reduced weight gain relative to vehicle-treated HF-fed mice in Nrf2+/+ mice. Decreased liver triglyceride and cholesterol levels, reduced mRNA expression of Adrp, suppressed expression of lipogenic transcription factors (Srebf1, Lxra, Xbp1s) and their target lipid synthesis enzymes, and increased mRNA for lipid export genes (Mttp, ApoB) relative to vehicle controls in Nrf2+/+ mice. Reduced hepatic protein levels of phospho-Ire1α, Xbp1s, p58IPK, phospho-eIf2α, and Atf4 relative to vehicle controls in Nrf2+/+ mice. Attenuated nuclear accumulation of NF-κB p65 and p50, and reduced mRNA for Cox2 and Nos2 relative to vehicle controls in Nrf2+/+ mice. Decreased hepatic malondialdehyde and protein carbonyl levels, and increased GSH/GSSG ratio relative to vehicle controls in Nrf2+/+ mice. Reduced NAFLD Activity Score (NAS) from 2.125 to 1.0, with decreased steatosis and fibrosis relative to vehicle controls in Nrf2+/+ mice. Showed no improvement in glucose homeostasis, weight gain, liver steatosis, ER stress, inflammation, oxidative stress, or liver histology relative to vehicle controls in Nrf2-/- mice; did not reduce liver triglyceride/cholesterol levels, suppress lipogenic gene expression, or mitigate NAS in Nrf2-/- mice. |
|